Limitations of statin monotherapy for the treatment of dyslipidemia: A projection based on the Canadian lipid study - Observational

Current Medical Research and Opinion

Volumn 25, Issue 1, 2009, Pages 47-55

  Sénécal, Martin ^a   Fodor, George ^b   Gagné, Claude ^c   Genest, Jacques ^d   Lavoie, Marc André ^e   McPherson, Ruth ^b   Marentette, Michael ^a   Sebaldt, Rolf J ^f,g  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MONTREAL HEART INSTITUTE   (Canada)

^f FigP Software Incorporated   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

Dyslipidemia management; Hypercholesterolemia; LDL C; Lipoproteins; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CARDIOVASCULAR RISK; CHI SQUARE TEST; CLINICAL STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; OBSERVATIONAL STUDY; RISK REDUCTION; BLOOD; CANADA; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; MIDDLE AGED;

AGED; CANADA; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 64249094799     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802575734     Document Type: Article

References (30)

1. Leal J, Luengo-Fernandez R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:1610-1619 (Pubitemid 43954923)
2. Manuel DG, Leung M, Nguyen K, et al. Burden of cardiovascular disease in Canada. Can J Cardiol 2003;19:997-1004
3. Mensah GA, Brown DW. An overview of cardiovascular disease burden in the United States. Health Aff (Millwood) 2007;26:38-48
4. Tsuyuki RT, Shibata MC, Nilsson C, et al. Contemporary burden of illness of congestive heart failure in Canada. Can J Cardiol 2003;19:436-438 (Pubitemid 36603513)
5. Bennett SJ. Perceived threats of individuals recovering from myocardial infarction. Heart Lung 1992;21:322-326
6. Conn VS, Taylor SG, Wiman P. Anxiety, depression, quality of life, and self-care among survivors of myocardial infarction. Issues Ment Health Nurs 1991;12:321-331
7. Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996;58:99-110 (Pubitemid 126425883)
8. Miller PJ, Wikoff R. Spouses' psychosocial problems, resources, and marital functioning postmyocardial infarction. Prog Cardiovasc Nurs 1989;4:71-76
9. Grover SA, Ho V, Lavoie F, et al. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Arch Intern Med 2003;163:333-339
10. Johansen H. Living with heart disease: the working-age population. Health Rep 1999;10:33-45
11. Economic burden of illness in Canada, 1998. Services Canada, 2002. Available at: http://www.phac-aspc.gc.ca/publicat/ebic-femc98/. Accessed on 14 November 2008
12. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051 (Pubitemid 34014055)
13. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-282
14. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278 (Pubitemid 41416582)
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504 (Pubitemid 38477774)
16. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435 (Pubitemid 40471450)
17. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445 (Pubitemid 41627921)
18. McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006;22:913-927 (Pubitemid 44596492)
19. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100:1481-1492 (Pubitemid 29451714)
20. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-1080 (Pubitemid 38541684)
21. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565
22. Bourgault C, Davignon J, Fodor G, et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study - Observational (CALIPSO). Can J Cardiol 2005;21:1187-1193 (Pubitemid 43013529)
23. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423 (Pubitemid 36776152)
24. Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2006;191:135-146 (Pubitemid 46227412)
25. Clark LT, Maki KC, Galant R, et al. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med 2006;21:320-326
26. Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007;63:698-708 (Pubitemid 46753568)
27. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004;19:638-645
28. Lachaine J, Rinfret S, Merikle EP, et al. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J 2006;152:164-169 (Pubitemid 43974723)
29. Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-599 (Pubitemid 40315319)
30. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-160 (Pubitemid 36835963)